The choice of contrast agent is an important intra-procedural consideration and has evolved considerably over the last several years with the development of low- and iso-osmolar contrast agents. Traditional iodine-based contrast agents were hypertonic and included ionic compounds such as diatrizoate (Hypaque, Renografin) that frequently caused mild hemodynamic changes in addition to contrast-related nephropathy. Given substantially lower costs in recent years, most laboratories have switched to the routine use of low-osmolar, non-ionic contrast agents for improved hemodynamic effects and patient comfort. An important effect of low-osmolar agents is believed to be reductions in contrast-related nephropathy. In a meta-analysis that included data from 25 trials, the risk of contrast-related nephropa-thy was 39% lower in patients who received low-osmolar contrast agents, compared with hypertonic contrast agents.69 This benefit appeared to be even more pronounced in patients with preexisting renal disease, with a 50% risk reduction in that population.
More recently, the introduction of iodixanol (Visi-paque), an iso-osmolar contrast agent, has raised the question of whether the incidence of contrast-related nephropathy can be further reduced. In a widely cited study of patients with CKD and diabetes melli-tus, the use of iso-osmolar contrast agents reduced the incidence of contrast-related nephropathy by more than 90%, compared with low-osmolar contrast agents.70 An additional study comparing these two types of contrast agents also suggested a reduction in major adverse cardiovascular events with the use of iso-osmolar contrast in patients undergoing high-risk PCI.71
Finally, some investigators have begun to use alternative, non-iodine-based contrast agents such as gadolinium, particularly for peripheral angiography. Although case reports of its use in the coronary circulation do exist, many questions remain regarding the overall safety and feasibility of this approach, particularly given the high serum osmolality of these agents.72,73
Regardless of the selection of a contrast agent, it is imperative that the least amount of volume required for adequate visualization of the coronary artery and technical success of the procedure be used. For patients who are at particularly high risk, the maximum allowable contrast dose should be calculated before the procedure, so that the interventional cardiologist and team can be aware of its use during the procedure. Staging of nonurgent procedures is also a possibility in many settings and will minimize the risk of developing contrast-related nephropathy. Unfortunately, there are few data on how long one should wait before staging procedures.
1. Persson PB, Tepel M: Contrast medium-induced nephropathy: The pathophysiology. Kidney Int Suppl 2006;(100):S8-S10.
2. Katholi RE, Woods WT Jr, Taylor GJ, et al: Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998;32:64-71.
3. Toprak O, Cirit M: Risk factors for contrast-induced nephropa-thy. Kidney Blood Press Res 2006;29:84-93.
4. Fukumoto Y, Tsutsui H, Tsuchihashi M, et al: The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: A prospective study. J Am Coll Cardiol 2003;42:211-216.
5. Mannesse CK, Blankestijn PJ, Man in 't Veld AJ, et al: Renal failure and cholesterol crystal embolization: A report of 4 surviving cases and a review of the literature. Clin Nephrol 1991;36:240-245.
6. Erley C: Concomitant drugs with exposure to contrast media. Kidney Int Suppl 2006;(100):S20-S24.
7. Hyman BT, Landas SK, Ashman RF, et al: Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987;82:1233-1237.
8. Barrett BJ, Parfrey PS: Clinical practice: Preventing nephropa-thy induced by contrast medium. N Engl J Med 2006; 354:379-386.
9. Mehran R, Nikolsky E: Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int Suppl 2006;(100):S11-S15.
10. Cigarroa RG, Lange RA, Williams RH, et al: Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86:649-652.
11. Freeman RV, O'Donnell M, Share D, et al: Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002;90:1068-1073.
12. Mehran R, Aymong ED, Nikolsky E, et al: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004;44:1393-1399.
13. McCullough PA, Sandberg KR: Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003;4(Suppl 5): S3-S9.
14. Blackman DJ, Pinto R, Ross JR, et al: Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J 2006;151:146-152.
15. Sadeghi HM, Stone GW, Grines CL, et al: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108: 2769-2775.
16. McCullough PA, Wolyn R, Rocher LL, et al: Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
17. Rihal CS, Textor SC, Grill DE, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
18. Marenzi G, Lauri G, Assanelli E, et al: Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44: 1780-1785.
19. Bartholomew BA, Harjai KJ, Dukkipati S, et al: Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515-1519.
20. Gupta R, Gurm HS, Bhatt DL, et al: Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv 2005;64:442-448.
21. Coresh J, Astor BC, Greene T, et al: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
22. Hsu CY, Lin F, Vittinghoff E, et al: Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003;14:2902-2907.
23. U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005.
24. Tarver-Carr ME, Powe NR, Eberhardt MS, et al: Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A population-based study of potential explanatory factors. J Am Soc Nephrol 2002; 13:2363-2370.
25. Kinchen KS, Sadler J, Fink N, et al: The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002;137:479-486.
26. Powe NR, Melamed ML: Racial disparities in the optimal delivery of chronic kidney disease care. Med Clin North Am 2005;89:475-488.
27. Best PJ, Reddan DN, Berger PB, et al: Cardiovascular disease and chronic kidney disease: Insights and an update. Am Heart J 2004;148:230-242.
28. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group [comment]. Ann Intern Med 1999;130: 461-470.
29. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39:S1-S266.
30. Stevens LA, Coresh J, Greene T, et al: Assessing kidney function: Measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483.
31. Knight EL, Verhave JC, Spiegelman D, et al: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65:1416-1421.
32. Go AS, Chertow GM, Fan D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
33. Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
34. Patel UD, Young EW, Ojo AO, et al: CKD progression and mortality among older patients with diabetes. Am J Kidney Dis 2005;46:406-414.
36. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [comment] [erratum appears in JAMA 2003 Jul 9;290(2):197]. JAMA 2003;289:2560-2572.
37. Shlipak MG, Fried LF, Cushman M, et al: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 2005;293:1737-1745.
38. Anavekar NS, McMurray JJ, Velazquez EJ, et al: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295.
39. Lindner A, Charra B, Sherrard DJ, et al: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
40. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
41. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853-906.
42. Hamani A, Petitclerc T, Jacobs C, et al: Is dialysis indicated immediately after administration of iodinated contrast agents in patients on haemodialysis? Nephrol Dial Transplant 1998; 13:1051-1052.
43. Deray G: Dialysis and iodinated contrast media. Kidney Int Suppl 2006;(100):S25-S29.
44. Bocksch W, Fateh-Moghadam S, Mueller E, et al: Percutaneous coronary intervention in patients with end-stage renal disease. Kidney Blood Press Res 2005;28:275-279.
45. Azar RR, Prpic R, Ho KK, et al: Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stent-ing. Am J Cardiol 2000;86:485-489.
46. Rubenstein MH, Harrell LC, Sheynberg BV, et al: Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000; 102:2966-2972.
47. Daemen J, Lemos P, Aoki J, et al: Treatment of coronary artery disease in dialysis patients with sirolimus-eluting stents: 1-Year clinical follow-up of a consecutive series of cases. J Invasive Cardiol 2004;16:685-687.
48. Halkin A, Mehran R, Casey CW, et al: Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: Results from the TAXUS-IV Trial. Am Heart J 2005; 150: 1163-1170.
49. Reddan DN, Szczech LA, Tuttle RH, et al: Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 2003;14:2373-2380.
50. Williams M: Coronary revascularization in diabetic chronic kidney disease/end-stage renal disease: A nephrologist's perspective. Clin J Am Soc Nephrol 2006;1:209-220.
51. Freeman RV, Mehta RH, Al Badr W, et al: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycopro-tein IIb/IIIa inhibitors. J Am Coll Cardiol 2003;41:718-724.
52. Alexander KP, Chen AY, Roe MT, et al: Excess dosing of anti-platelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294:3108-3116.
53. Solomon R, Werner C, Mann D, et al: Effects of saline, man-nitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331:1416-1420.
54. Mueller C, Buerkle G, Buettner HJ, et al: Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336.
55. Taylor AJ, Hotchkiss D, Morse RW, et al: PREPARED: Preparation for Angiography in Renal Dysfunction: A randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998;114:1570-1574.
56. Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004;291:2328-2334.
57. Nallamothu BK, Shojania KG, Saint S, et al: Is acetylcysteine effective in preventing contrast-related nephropathy? A metaanalysis. Am J Med 2004;117:938-947.
58. Tepel M, van der Giet M, Schwarzfeld C, et al: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
59. Baker CS, Wragg A, Kumar S, et al: A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J Am Coll Cardiol 2003;41:2114-2118.
60. Marenzi G, Assanelli E, Marana I, et al: N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-2782.
61. Madyoon H, Croushore L, Weaver D, et al: Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv 2001;53:341-345.
62. Kini AS, Mitre CA, Kamran M, et al: Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldo-pam. Am J Cardiol 2002;89:999-1002.
63. Stone GW, McCullough PA, Tumlin JA, et al: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA 2003;290:2284-2291.
64. Spargias K, Alexopoulos E, Kyrzopoulos S, et al: Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:2837-2842.
65. Bagshaw SM, Ghali WA: Theophylline for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. Arch Intern Med 2005;165:1087-1093.
66. Stevens MA, McCullough PA, Tobin KJ, et al: A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: Results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999;33:403-411.
67. Marenzi G, Bartorelli AL: Hemofiltration in the prevention of radiocontrast agent induced nephropathy. Minerva Anestesiol 2004;70:189-191.
68. Michishita I, Fujii Z: A novel contrast removal system from the coronary sinus using an adsorbing column during coronary angiography in a porcine model. J Am Coll Cardiol 2006;47:1866-1870.
69. Barrett BJ, Carlisle EJ: Metaanalysis of the relative nephrotox-icity of high- and low-osmolality iodinated contrast media. Radiology 1993;188:171-178.
70. Aspelin P, Aubry P, Fransson SG, et al: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-499.
71. Davidson CJ, Laskey WK, Hermiller JB, et al: Randomized trial of contrast media utilization in high-risk PTCA: The COURT trial. Circulation 2000;101:2172-2177.
72. Sarkis A, Badaoui G, Azar R, et al: Gadolinium-enhanced coronary angiography in patients with impaired renal function. Am J Cardiol 2003;91:974-975, A4.
73. Bokhari SW, Wen YH, Winters RJ: Gadolinium-based percutaneous coronary intervention in a patient with renal insufficiency. Catheter Cardiovasc Interv 2003;58:358-361.
Was this article helpful?
All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.